Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin A  COVID-19 treatment studies for Vitamin A  C19 studies: Vitamin A  Vitamin A   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -50% Improvement Relative Risk Ventilation 0% ICU admission 25% Improvement -76% Hospitalization time -8% c19early.org/va Somi et al. Vitamin A for COVID-19 RCT LATE TREATMENT Favors vitamin A Favors control
Effect of vitamin A supplementation on the outcome severity of COVID-19 in hospitalized patients: A pilot randomized clinical trial
Somi et al., Nutrition and Health, doi:10.1177/02601060221129144
7 Oct 2022    Source   PDF   Share   Tweet
RCT 30 hospitalized patients in Iran, showing no significant difference with vitamin A treatment. All patients received HCQ. 50,000 IU/day intramuscular vitamin A for up to 2 weeks.
risk of death, 50.0% higher, RR 1.50, p = 1.00, treatment 3 of 15 (20.0%), control 2 of 15 (13.3%).
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 3 of 15 (20.0%), control 3 of 15 (20.0%).
risk of ICU admission, 25.0% lower, RR 0.75, p = 1.00, treatment 3 of 15 (20.0%), control 4 of 15 (26.7%), NNT 15.
risk of no improvement, 76.0% higher, HR 1.76, p = 0.21, treatment 15, control 15, time to clinical response, Kaplan–Meier.
hospitalization time, 8.1% higher, relative time 1.08, p = 0.49, treatment mean 7.33 (±2.31) n=15, control mean 6.78 (±1.84) n=15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Somi et al., 7 Oct 2022, Randomized Controlled Trial, Iran, peer-reviewed, mean age 60.2, 7 authors.
Contact: znikniaz@hotmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin AAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit